These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15717941)

  • 1. Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
    Cooney MM; Ortiz J; Bukowski RM; Remick SC
    Curr Oncol Rep; 2005 Mar; 7(2):90-5. PubMed ID: 15717941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular targeting agents as cancer therapeutics.
    Thorpe PE
    Clin Cancer Res; 2004 Jan; 10(2):415-27. PubMed ID: 14760060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combretastatin A4 phosphate: background and current clinical status.
    Young SL; Chaplin DJ
    Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Siemann DW; Chaplin DJ; Walicke PA
    Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combretastatin A-4 vascular damage to tumours.
    O'Brien C
    Mol Med Today; 1997 Sep; 3(9):369. PubMed ID: 9302685
    [No Abstract]   [Full Text] [Related]  

  • 7. The first international conference on vascular targeting: meeting overview.
    Thorpe PE; Chaplin DJ; Blakey DC
    Cancer Res; 2003 Mar; 63(5):1144-7. PubMed ID: 12615734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug based approaches for targeting tumor vasculature: development of combretastatin A4 phosphate.
    Chaplin DJ
    Pathophysiol Haemost Thromb; 2003; 33 Suppl 1():9-10. PubMed ID: 12954990
    [No Abstract]   [Full Text] [Related]  

  • 9. Vascular-targeting therapies for treatment of malignant disease.
    Siemann DW; Chaplin DJ; Horsman MR
    Cancer; 2004 Jun; 100(12):2491-9. PubMed ID: 15197790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combretastatin A4 phosphate: a novel vascular disrupting agent.
    Nagaiah G; Remick SC
    Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumour vasculature: the development of combretastatin A4.
    Griggs J; Metcalfe JC; Hesketh R
    Lancet Oncol; 2001 Feb; 2(2):82-7. PubMed ID: 11905799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
    Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
    Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.
    Marrelli M; Conforti F; Statti GA; Cachet X; Michel S; Tillequin F; Menichini F
    Curr Med Chem; 2011; 18(20):3035-81. PubMed ID: 21651481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
    Vincent L; Kermani P; Young LM; Cheng J; Zhang F; Shido K; Lam G; Bompais-Vincent H; Zhu Z; Hicklin DJ; Bohlen P; Chaplin DJ; May C; Rafii S
    J Clin Invest; 2005 Nov; 115(11):2992-3006. PubMed ID: 16224539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combretastatin A4 phosphate.
    West CM; Price P
    Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
    Cai YC; Zou Y; Xian LJ
    Yao Xue Xue Bao; 2010 Mar; 45(3):283-8. PubMed ID: 21351502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
    Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
    Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
    Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
    Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft.
    Fu XH; Li J; Zou Y; Hong YR; Fu ZX; Huang JJ; Zhang SZ; Zheng S
    Cancer Lett; 2011 Dec; 312(1):109-16. PubMed ID: 21893381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.